MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/neuonc/noae111

Медицинская библиотека · Neuro-oncology · 2024

Medulloblastoma in children with Fanconi anemia: Association with FA-D1/FA-N, SHH type and poor survival independent of treatment strategies.

Sönksen Marthe, Obrecht-Sturm Denise, Hernáiz Driever Pablo, Sauerbrey Axel, Graf Norbert, Kontny Udo, Reimann Christian, Langhein Mina, Kordes Uwe R, Schwarz Rudolf, Obser Tobias, Boschann Felix, Schüller Ulrich, Altendorf Lea, Goschzik Tobias, Pietsch Torsten, Mynarek Martin, Rutkowski Stefan

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The outcome of children with medulloblastoma (MB) and Fanconi Anemia (FA), an inherited DNA repair deficiency, has not been described systematically. Treatment is complicated by high vulnerability to treatment-associated side effects, yet structured data are lacking. This study aims to give a comprehensive overview of clinical and molecular characteristics of pediatric FA MB patients.

METHODS

Clinical data including detailed information on the treatment and toxicities of 6 previously unreported FA MB patients were supplemented with data of 16 published cases.

RESULTS

We identified 22 cases of children with FA and MB with clinical data available. All MBs with subgroup reporting were SHH-activated (n = 9), confirmed by methylation profiling in 5 patients. FA MB patients exclusively belonged to complementation groups FA-D1 (n = 16) or FA-N (n = 3). Patients were treated with postoperative chemotherapy only (50%) or radiotherapy (RT) ± chemotherapy (27%). Of 23% did not receive adjuvant therapy. Excessive treatment-related toxicities were frequent. Severe hematological toxicity occurred in 91% of patients treated with alkylating chemotherapy, while non-alkylating agents and RT were less toxic. Median overall survival (OS) was 1 year (95%CI: 0.3-1.8). 1-year-progression-free-survival (PFS) was 26.3% ± 10.1% and 1-year-OS was 42.1% ± 11.3%. Adjuvant therapy prolonged survival (1y-OS/1y-PFS 0%/0% without adjuvant therapy vs. 53.3% ± 12.9%/33.3 ± 12.2% with adjuvant therapy, P = .006/P = .086).

CONCLUSIONS

MB in FA patients is strongly associated with SHH activation and FA-D1/FA-N. Despite the dismal prognosis, adjuvant therapy may prolong survival. Non-alkylating chemotherapy and RT are feasible in selected patients with careful monitoring of toxicities and dose adjustments. Curative therapy for FA MB-SHH remains an unmet medical need.

Для цитирования: Sönksen Marthe, Obrecht-Sturm Denise, Hernáiz Driever Pablo, Sauerbrey Axel, Graf Norbert, Kontny Udo, Reimann Christian, Langhein Mina, Kordes Uwe R, Schwarz Rudolf, Obser Tobias, Boschann Felix, Schüller Ulrich, Altendorf Lea, Goschzik Tobias, Pietsch Torsten, Mynarek Martin, Rutkowski Stefan. Medulloblastoma in children with Fanconi anemia: Association with FA-D1/FA-N, SHH type and poor survival independent of treatment strategies.. Neuro-oncology. 2024. DOI: 10.1093/neuonc/noae111.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.